Since then, the clinical importance of tumor protein p53 (TP53) abnormalities, deletions involving chromosomes 1p and 19q, MGMT promoter methylation status, abnormalities in the PTEN tumor suppressor gene and the BRAF oncogene, and IDH mutations in gliomas have become better illuminated (5, 24, 25). This evidence concerns the gene BRAF and glioma.